Difference between revisions of "Soft tissue sarcoma - historical"
Jump to navigation
Jump to search
| Line 21: | Line 21: | ||
!style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
| − | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647653/ Tap et al. 2016 (CP15-0806)] |
| style="background-color:#1a9851" |Randomized Phase II (E-RT-esc) | | style="background-color:#1a9851" |Randomized Phase II (E-RT-esc) | ||
|[[Soft_tissue_sarcoma#Doxorubicin_monotherapy|Doxorubicin]] | |[[Soft_tissue_sarcoma#Doxorubicin_monotherapy|Doxorubicin]] | ||
| Line 38: | Line 38: | ||
===References=== | ===References=== | ||
| − | # '''CP15-0806:''' Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30;388(10043):488-97. Epub 2016 Jun 9. Erratum in: Lancet. 2016 Jul 30;388(10043):464. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30587-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27291997 PubMed] | + | # '''CP15-0806:''' Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30;388(10043):488-97. Epub 2016 Jun 9. Erratum in: Lancet. 2016 Jul 30;388(10043):464. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30587-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647653/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27291997 PubMed] |
[[Category:Soft tissue sarcoma regimens]] | [[Category:Soft tissue sarcoma regimens]] | ||
Revision as of 04:19, 30 January 2020
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main soft tissue sarcoma page for current regimens.
2 regimens on this page
4 variants on this page
|
Locally advanced or metastatic disease, combination regimens
Doxorubicin & Olaratumab
| back to top |
Regimen
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Tap et al. 2016 (CP15-0806) | Randomized Phase II (E-RT-esc) | Doxorubicin | Superior OS |
Chemotherapy
- Doxorubicin (Adriamycin) as follows:
- Cycles 1 to 8: 75 mg/m2 IV once on day 1
- Olaratumab (Lartruvo) 15 mg/kg IV once per day on days 1 & 8
21-day cycles
Supportive medications
- CP15-0806, optional: Dexrazoxane (Zinecard) (dose not specified) IV once on day 1
References
- CP15-0806: Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30;388(10043):488-97. Epub 2016 Jun 9. Erratum in: Lancet. 2016 Jul 30;388(10043):464. link to original article contains verified protocol link to PMC article PubMed